These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33649757)

  • 1. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.
    Hasselbalch HC; Elvers M; Schafer AI
    Blood; 2021 Apr; 137(16):2152-2160. PubMed ID: 33649757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms.
    Schafer AI
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):305-324. PubMed ID: 33641871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
    Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
    BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
    Marin Oyarzún CP; Heller PG
    Front Immunol; 2019; 10():1373. PubMed ID: 31258539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mean platelet volume and risk of thrombotic and bleeding complications in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
    Krashin E; Cohen O; Pereg D; Lishner M; Leader A
    Blood Coagul Fibrinolysis; 2018 Apr; 29(3):288-293. PubMed ID: 29474204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic and bleeding complications in classical myeloproliferative neoplasms.
    McMahon B; Stein BL
    Semin Thromb Hemost; 2013 Feb; 39(1):101-11. PubMed ID: 23264112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.
    Reeves BN; Beckman JD
    Curr Hematol Malig Rep; 2021 Jun; 16(3):304-313. PubMed ID: 33876389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
    Sun T; Zhang L
    Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of leukocytes in myeloproliferative neoplasm thromboinflammation.
    Liu Y; Wang Y; Huang G; Wu S; Liu X; Chen S; Luo P; Liu C; Zuo X
    J Leukoc Biol; 2024 May; 115(6):1020-1028. PubMed ID: 38527797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
    Bhuria V; Baldauf CK; Schraven B; Fischer T
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective.
    Feng Y; Zhang Y; Shi J
    Platelets; 2022 Oct; 33(7):955-963. PubMed ID: 35081860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloproliferative Neoplasms in Children and Adolescents and Thrombosis at Unusual Sites: The Role of Driver Mutations.
    Tafesh L; Musgrave K; Roberts W; Plews D; Carey P; Biss T
    J Pediatr Hematol Oncol; 2019 Aug; 41(6):490-493. PubMed ID: 29668539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombosis in myeloproliferative neoplasms.
    Falanga A; Marchetti M
    Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are MPNs vascular diseases?
    Finazzi G; De Stefano V; Barbui T
    Curr Hematol Malig Rep; 2013 Dec; 8(4):307-16. PubMed ID: 24037420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Sankar K; Stein BL; Rampal RK
    Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms.
    Teofili L; Martini M; Iachininoto MG; Capodimonti S; Nuzzolo ER; Torti L; Cenci T; Larocca LM; Leone G
    Blood; 2011 Mar; 117(9):2700-7. PubMed ID: 21212285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms.
    Seguro FS; Teixeira LLC; da Rosa LI; da Silva WF; Nardinelli L; Bendit I; Rocha V
    J Thromb Thrombolysis; 2020 May; 49(4):667-672. PubMed ID: 31898273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience.
    Kissova J; Ovesna P; Bulikova A; Zavřelova J; Penka M
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):448-53. PubMed ID: 25828967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.